[Form 4] CRISPR Therapeutics AG Insider Trading Activity
Rhea-AI Filing Summary
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju reported a mix of equity awards, an option exercise, and a mandated share sale. On March 20, 2026, he received a stock option covering 38,499 Common Shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting April 20, 2026. He was also granted 27,500 restricted stock units (RSUs), scheduled to vest in four annual tranches from March 20, 2027 through March 20, 2030.
On the same date, 6,250 RSUs from a prior 2024 award vested and were converted into 6,250 Common Shares. On March 23, 2026, Raju sold 3,708 Common Shares at an average price of $46.78 per share. A footnote states this sale was required to cover tax withholding on the RSU vesting under the company’s RSU Settlement Policy and "does not represent a discretionary trade". After these transactions, he directly held 15,565 Common Shares, which remain subject to a lock-up agreement related to the issuer’s convertible senior notes due 2031.
Positive
- None.
Negative
- None.
Insights
Routine equity grants and tax-driven sale; no clear directional signal.
The transactions show CRISPR Therapeutics AG awarding its CFO a sizable long-term equity package: a stock option over 38,499 shares at $46.24 and 27,500 RSUs with vesting stretching from 2027 to 2030. This aligns his compensation with future share performance.
The 6,250 RSUs that vested and converted into common stock, followed by the sale of 3,708 shares at $46.78, are characterized in the footnotes as required to satisfy tax withholding obligations under an internal policy, rather than a discretionary portfolio decision. That framing reduces the informational content of the sale for interpreting sentiment.
Post-transaction, the CFO directly holds 15,565 Common Shares, subject to a lock-up tied to convertible senior notes due 2031. The combination of new grants, vesting, and a policy-driven sale is typical of executive compensation mechanics and, on its own, does not materially alter the broader investment case.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Shares | 3,708 | $46.78 | $173K |
| Grant/Award | Stock Option (Right to Buy) | 38,499 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 27,500 | $0.00 | -- |
| Exercise | Restricted Stock Units | 6,250 | $0.00 | -- |
| Exercise | Common Shares | 6,250 | $0.00 | -- |
Footnotes (1)
- These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026. This restricted stock unit award was granted on March 20, 2026 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.
